Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda

Journal of Infectious Diseases

Volumn 200, Issue 11, 2009, Pages 1650-1657

  Nawaz, Fatima ^a   Nsobya, Samuel L ^b   Kiggundu, Moses ^b   Joloba, Moses ^b   Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; DEETHYLAMODIAQUINE; FANSIDAR;

ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CLINICAL TRIAL; DRUG RESPONSE; GENE; GENETIC POLYMORPHISM; HUMAN; IC 50; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; PFMDR1 GENE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MOLECULAR SEQUENCE DATA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PYRIMETHAMINE; SEQUENCE ALIGNMENT; SULFADOXINE; UGANDA;

EID: 72849125937     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/647988     Document Type: Article

References (50)

1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-218
2. World Health Organization (WHO). Guidelines for the treatment of malaria. Geneva: WHO, 2006.
3. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-334
4. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77:181-192
5. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparummalaria in Kampala, Uganda: randomised clinical trial. Lancet 2004; 364: 1950-1957
6. Yeka A, Banek K, Bakyaita N, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2005; 2:e190. (Pubitemid 46179276) (Pubitemid 46179276)
7. Martensson A, Stromberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005; 41:1079-1086
8. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365: 1474-1480 (Pubitemid 40591692) (Pubitemid 40591692)
9. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210-2219
10. Mockenhaupt FP, Ehrhardt S, Dzisi SY, et al. A randomized, placebocontrolled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 2005; 10:512-520 (Pubitemid 40806656) (Pubitemid 40806656)
11. Zongo I, Dorsey G, Rouamba N, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369:491-498 (Pubitemid 46223467) (Pubitemid 46223467)
12. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008; 52:1589-1596 (Pubitemid 351614647) (Pubitemid 351614647)
13. Zongo I, Dorsey G, Rouamba N, et al. Amodiaquine, sulfadoxinepyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am J Trop Med Hyg 2005; 73:826-832 (Pubitemid 41688453) (Pubitemid 41688453)
14. Nsimba B, Guiyedi V, Mabika-Mamfoumbi M, et al. Sulphadoxine/ pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy. Malar J 2008; 7:31.
15. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996; 30:263-299
16. Childs GE, Boudreau EF, Milhous WK, et al. A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg 1989; 40:7-11.
17. Basco LK, Ringwald P. Molecular epidemiology of malaria in Cameroon. XXIV. Trends of in vitro antimalarial drug responses in Yaounde, Cameroon. Am J Trop Med Hyg 2007; 76:20-26 (Pubitemid 351627796)
18. Agnamey P, Brasseur P, de Pecoulas PE, Vaillant M, Olliaro P. Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance southwestern Senegal) during the first 5 years of routine use of artesunate-amodiaquine. Antimicrob Agents Chemother 2006; 50: 1531-1534
19. Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother 2006; 50:3343-3349
20. Pradines B, Hovette P, Fusai T, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 2006; 44:2404-2408
21. Sasi P, Abdulrahaman A, Mwai L, et al. In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa. J Infect Dis 2009; 199:1575-1582
22. Echeverry DF, Holmgren G, Murillo C, et al. Polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Am J Trop Med Hyg 2007; 77:1034-1038
23. Long GW, Watt G, Sy N, Buck RL, Sangalang RP Jr, Ranoa CP. In vitro drug response of Plasmodium falciparum in the Philippines: increased resistance to amodiaquine. Southeast Asian J Trop Med Public Health 1987; 18:202-206
24. Restrepo-Pineda E, Arango E, Maestre A, Do Rosario VE, Cravo P. Studies on antimalarial drug susceptibility in Colombia, in relation to Pfmdr1 and Pfcrt. Parasitology 2008; 135:547-553 (Pubitemid 351572128) (Pubitemid 351572128)
25. Yang HL, Liu DQ, Yang YM, et al. In vitro sensitivity of Plasmodium falciparum to eight antimalarials in China-Myanmar and China-Lao PDR border areas. Southeast Asian J Trop Med Public Health 1997; 28:460-464
26. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861-871
27. Ochong EO, van den Broek IV, Keus K, Nzila A. Association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 2003; 69:184-187
28. Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg 2006; 75:162-165
29. Happi CT, Gbotosho GO, Folarin OA, et al. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg 2006; 75:155-161
30. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol 2006; 6:309-314 (Pubitemid 43785813) (Pubitemid 43785813)
31. Djimde AA, Fofana B, Sagara I, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg 2008; 78:455-461 (Pubitemid 351845197)
32. Menard D, Yapou F, Manirakiza A, Djalle D, Matsika-Claquin MD, Talarmin A. Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am J Trop Med Hyg 2006; 75:381-387
33. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002; 298:210-213
34. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403:906-909
35. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother 2007; 51:3023-3025
36. Davis JC, Clark TD, Kemble SK, et al. Longitudinal study of urban malaria in a cohort of Ugandan children: description of study site, census and recruitment. Malar J 2006; 5:18.
37. World Health Organization (WHO). Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: WHO, 2003.
38. Noedl H, Yingyuen K, Laoboonchai A, Fukuda M, Sirichaisinthop J, Miller RS. Sensitivity and specificity of an antigen detection ELISA for malaria diagnosis. Am J Trop Med Hyg 2006; 75:1205-1208 (Pubitemid 351627509)
39. Basco L. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva: World Health Organization, 2007.
40. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M,Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 2000; 108:13-23.
41. Dorsey G, Kamya MR, Singh A, Rosenthal PJ. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis 2001; 183:1417-1420
42. 2. Staedke SG, Kamya MR, Dorsey G, et al. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 2001; 358:368-374 (Pubitemid 32739098) (Pubitemid 32739098)
43. Rason MA, Andrianantenaina HB, Ariey F, Raveloson A, Domarle O, Randrianarivelojosia M. Prevalent pfmdr1 n86y mutant Plasmodium falciparum in Madagascar despite absence of pfcrt mutant strains. Am J Trop Med Hyg 2007; 76:1079-1083
44. Quashie NB, Duah NO, Abuaku B, Koram KA. The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs. Ann Trop Med Parasitol 2007; 101:391-398
45. Tinto H, Rwagacondo C, Karema C, et al. In-vitro susceptibility of Plasmodium falciparum tomonodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg 2006; 100:509-514
46. Menard D, Djalle D, Manirakiza A, et al. Drug-resistant malaria in Bangui, Central African Republic: an in vitro assessment. Am J Trop Med Hyg 2005; 73:239-243 (Pubitemid 41278691)
47. Aubouy A, Mayombo J, Keundjian A, Bakary M, Le Bras J, Deloron P. Lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am J Trop Med Hyg 2004; 71:294-296
48. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007; 82:197-203. (Pubitemid 47075331) (Pubitemid 47075331)
49. Nsobya SL, Kiggundu M, Joloba M, Dorsey G, Rosenthal PJ. Complexity of Plasmodium falciparum clinical samples from Uganda during short-term culture. J Infect Dis 2008; 198:1554-1557
50. Purfield A, Nelson A, Laoboonchai A, et al. A new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCR. Malar J 2004; 3:9.